Tags : Retrotope

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal

Shots: The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD, a neurodegeneration associated with PLA2G6 EMA’s ODD is granted to the drug offering treatments for rare, devastating, fatal, and untreated diseases affecting fewer than 200,000 people or >200,000 persons Retrotope’s RT001 is an oral deuterated polyunsaturated fatty acid (D-PUFA) working […]Read More